secwatch.observer — SEC 8-K summary
======================================

Issuer:     SeaStar Medical Holding Corp (ICU)
CIK:        0001831868
Form:       8-K
Filed at:   2025-03-27T23:59:59+00:00
Accession:  0000950170-25-046069
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SeaStar Medical reports FY2024 net loss $24.8M; first product revenue $0.1M from QUELIMMUNE launch
--------------------------------------------------------------------------------

- Net loss for 2024 was $24.8M ($6.63 per share) vs $26.2M ($30.26) in 2023.
- First net revenue of $0.1M from QUELIMMUNE pediatric AKI therapy approved via HDE in Q1 2024.
- NEUTRALIZE AKI pivotal trial enrolled 94 of 200 patients; added 14 sites in 2024.
- Raised ~$31M in capital and reduced debt; $6M registered direct financing completed Feb 2025.
- Cash and short-term investments $1.8M at Dec 31, 2024, before February financing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831868/000095017025046069/0000950170-25-046069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831868/000095017025046069/icu-20250327.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-046069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer